The use of enzyme inhibitors to clarify the role of thromboxane A2 in vasoocclusive disease has been complicated by their nonspecific action. To address this problem we have examined the effects of thromboxane A2/prostaglandin endoperoxide receptor antagonism in a canine model of platelet-dependent coronary occlusion. Two structurally distinct thromboxane A2/prostaglandin endoperoxide receptor antagonists, 3-carboxyl-dibenzo and/or endoperoxide formation in vivo.
Introduction
Thromboxane A2 is the major metabolite of arachidonic acid in platelets formed via cyclic prostaglandin endoperoxides by the enzymes cyclooxygenase and thromboxane synthase (1) . In vitro, thromboxane A2 induces vascular smooth muscle contraction and platelet aggregation (1) . However, its evanescent nature has precluded direct study in vivo, so that its putative role in vascular occlusion is based largely on indirect evidence using inhibitors of the thromboxane A2 synthase and cyclooxygenase enzymes (2) . Interpretation of these studies has been Address correspondence to Dr. D. J. Fitzgerald. Receivedfor publication 1 April 1985 and in revisedform 15 October 1985.
complicated by the nonspecific action ofthese agents (3) (4) (5) (6) . More recently, several compounds have been described that antagonize the effects ofthromboxane A2 and prostaglandin endoperoxides at the common receptor site for these proaggregatory vasoconstrictor compounds (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . A theoretical limitation to using such compounds as antithrombotic agents in vivo is that platelet agonists such as collagen may permit continued thromboxane independent platelet activation despite efficient receptor blockade.
To elucidate the role of thromboxane A2/prostaglandin endoperoxide receptor activation during platelet-dependent vascular occlusion, we have studied two structurally distinct receptor antagonists, 3-carboxyl-dibenzo (b,f)thiepin-5,5-dioxide (L636,499)' (13, 14) and (IS-(la,2,(5Z),3,,4a))-7-(3- 
Methods
Animal experiments. The model used was a modification ofthat described by Luchessi and co-workers (17) . Mongrel dogs (18-32 kg) were anesthetized with sodium pentobarbital (30 mg/kg plus a continuous infusion intravenously) and ventilated with room air by positive pressure ventilation (Harvard respirator pump; Harvard Apparatus Co., Inc., S. Natick, MA). The heart was suspended in a pericardial cradle through a left thoracotomy in the fifth intercostal space and the left circumflex coronary artery was isolated proximal to the first marginal branch. An electrode was passed through the wall ofthe left circumflex coronary artery so that 4-5 mm ofexposed tip lay against the endothelial surface. The electrode consisted of 30-gauge silver-coated copper wire insulated with Teflon onto which was crimped the tip of a 28-gauge hypodermic needle to aid passage of the electrode through the vessel wall. The electrode was connected in series with a 9-V battery, an ammeter, a 20,000-0 resistor, and a 50,000-0 potentiometer, and the circuit completed by grounding to the subcutaneous tissues ( Fig. 1) . Arterial blood pressure was recorded through a polyethylene catheter in the femoral artery and, in some cases, through a 23-gauge needle in the left circumflex coronary artery distal to the electrode. Left circumflex coronary artery blood flow was recorded by a 2.0-3.0-mm electromagnetic flow probe (Gould Statham Instruments, Puerto Rico) positioned proximal to the electrode site. The femoral and jugular veins were cannulated for drug administration and blood withdrawal. All recordings were made simultaneously on a 6-channel physiological recorder (HP 1758A). After a 30-min stabilization period, L636,499 (10-30 mg/kg) or vehicle (NA2CO3 0.05 M) were administered intravenously over 10 min followed by a 10-min equilibration period before initiation of a 150-,uA current. Blood was withdrawn prior to, at I h after drug administration, and upon completion of the study for platelet aggregation studies for measurement of serum thromboxane B2 and serum drug concentrations. (25) .
Results
Animal studies. Passage of a 150-MA current through the circuit resulted in vessel occlusion in 1-2 h. On light microscopy, the occlusive thrombus consisted of a homogenous material with entrapped red blood cells. This material failed to stain for fibrin and was found to be largely composed of platelets on electron microscopy ( Fig. 2) . Treatment with the thromboxane A2jpros-taglandin endoperoxide receptor antagonist L636,499 intravenously, before passage ofa 150-MA current through the electrode, delayed the time to occlusion in a dose-dependent manner (Fig.   3 ). At 30 mg/kg of L636,499, the time to occlusion was 290±43 min (n = 7; mean±SEM) compared with 92±12 min for vehicletreated controls (n = 14; P < 0.01). The mean time to occlusion in treated dogs includes four dogs in whom occlusion failed to occur during 6 h of observation and who were assigned an occlusion time of 6 h. Similarly, treatment with 0.2 mg/kg SQ 29,548 plus 0.2 mg/kg per h intravenously throughout the duration ofthe experiment delayed the time to occlusion (229±5.9 min, n = 3) compared with vehicle-treated controls (50±22.0 min, n = 3). One SQ 29,548-treated dog failed to occlude during 4 h of observation and was assigned an occlusion time of 4 h. The shorter time to occlusion in SQ 29,548-treated dogs and their respective vehicle-treated controls reflects the higher current (200 AA) used in these experiments. There was no difference in arterial blood pressure or coronary blood flow between drugand vehicle-treated dogs.
In 5 control dogs, 30 mg/kg L636,499 administered intravenously 2 min after complete occlusion of the left circumflex coronary artery resulted in reperfusion (>80% of control coronary blood flow) in all cases. In two dogs, coronary flow was maintained during 1 h of subsequent observation during which current flow was continued (Fig. 4) , whereas in the remaining three dogs reocclusion occurred in <30 min. In contrast, administration of vehicle (n = 3) had no effect (Fig. 4) .
Platelet studies. In vitro experiments demonstrated that all three thromboxane A2/prostaglandin endoperoxide receptor antagonists, L636,499, SQ 29,548, and 13-APA, inhibited platelet aggregation induced by threshold concentrations of arachidonic acid and U46619 but not by ADP. L636,499 and 13-APA were almost equipotent; maximum inhibition of the response to the threshold concentration of U46619 occurred at 2 X l0-4 M (Fig. 5) . By contrast, SQ 29,548 was more potent, exhibiting a similar effect at 10-7 M.
Inhibition of coronary occlusion by L636,499 was associated with almost complete inhibition of platelet aggregation to the threshold concentration of U46619 but not to ADP ex vivo in all but one dog at 1 h after drug administration (Fig. 6) . Similarly, platelet aggregation to the threshold concentration of arachidonic acid was markedly inhibited (92±6%). Corresponding serum levels of L636,499 were 96.4±7.2 Mg/ml (3 X l0-4 M), which confirmed adequate bioavailability for a thromboxane A2Jpros-taglandin endoperoxide-mediated effect in vivo. Platelet aggregation to U46619 had at least partially recovered at the time of occlusion or at the end of the observation period. Thus, the degree ofinhibition ofU466 19-induced platelet aggregation was 59±15% at the time of occlusion compared with 82±12% at 1 h after initiation of the current. Similarly, platelet aggregation in response to threshold concentrations of arachidonic acid and U46619, but not to ADP, was completely inhibited ex vivo after administration of SQ 29,548 in all dogs (Fig. 6) . Serum thromboxane B2 decreased by 27±9.2% at 1 h following administration of L636,499, but was unaltered in control animals. Although no significant change in serum thromboxane B2 occurred after SQ 29,548 (Fig. 6) , this may reflect the small sample size.
Possible mechanisms for the reinstitution of coronary flow by L636,499 following occlusion in this model include disaggregation ofplatelets within the thrombus and relaxation of vascular smooth muscle contracted by thromboxane A2 which has been released locally at the occlusion site. To address the first mechanism, L636,499 was added to aspirinated (10' M) canine platelets aggregated with U46619 (1.25-2.5 AM) or with ADP (10-20 MM) in vitro. L636,499 caused a dose-and time-dependent disaggregation of canine platelets aggregated with U46619 ( Fig. 7 ) with all dogs (n = 7) demonstrating the effect at 7 X 10-M L636,499, but had no effect on ADP-induced platelet aggregation. Disaggregation was also demonstrated in whole blood after platelet aggregation with U46619. A similar effect was demonstrated using a structurally distinct thromboxane A2/ prostaglandin endoperoxide receptor antagonist, 13 ( Fig. 9) .
Discussion
These studies demonstrate the efficacy ofthromboxane A2/prostaglandin endoperoxide receptor antagonists in vivo in a model of thrombotic occlusion. Thus, they provide evidence for thromboxane A2/endoperoxide receptor activation as a predominant mechanism in this model of platelet-dependent coronary occlusion. This conclusion is based on the platelet de- pendency of the canine model used and on the pharmacological specificity of the compounds studied. The role of platelet activation in this model is illustrated by the morphological appearance of the occlusive material and by studies demonstrating inhibition of occlusion by prostacyclin but not heparin (17, 26) . Specificity of the pharmacological effects of L636,499 and SQ 29,548 was demonstrated in vitro and ex vivo. Thus, both compounds specifically inhibited platelet activation at the level of the common thromboxane A2/prostaglandin endoperoxide receptor. L636,499 is a specific antagonist of the platelet thromboxane A2/prostaglandin endoperoxide receptor at the concentrations attained in vivo, although it has weak antiserotonergic properties at higher concentrations (13, 14) . In addition, SQ 29,548 has no serotonin antagonist activity (16) . Consistent with their effects as thromboxane A2/prostaglandin endoperoxide receptor antagonists, these compounds did not increase cyclic AMP generation in platelet-rich plasma, as occurs with phosphodiesterase inhibitors and prostacyclin. Similarly, it is unlikely that these compounds mediate their effects through increased cyclic GMP generation since this would result in nonspecific inhibition ofplatelet aggregation and relaxation ofvascular smooth muscle (27, 28) , whereas the inhibitory effects of the compounds studied were specific for endoperoxide. Despite the lack of a direct response of canine platelets to thromboxane or prostaglandin endoperoxides in up to 70% of dogs (20) , these studies demonstrate an important functional role for thromboxane in this species. This is consistent with studies demonstrating effectiveness ofcyclooxygenase inhibitors in models of platelet-dependent vasoocclusion in dogs (17, (35) (36) (37) (38) . Canine platelets generate thromboxane, and thromboxane A2/prostaglandin endoperoxide receptors have been demonstrated in canine platelet preparations (39) . Priming of canine platelets in vitro has been shown not to alter either receptor density or affinity (39) , so that the lack of a direct response to thromboxane appears to be a post-receptor event and may be an in vitro artifact. The presence of a platelet thromboxane AJ prostaglandin endoperoxide receptor, the ability ofcanine platelets to generate thromboxane, and the functional importance of thromboxane in the canine are clearly defined and make this an appropriate species for these types of studies.
In conclusion, these studies demonstrate the efficacy and specificity of two thromboxane A2/prostaglandin endoperoxide receptor antagonists in vitro and in vivo and provide evidence that thromboxane A2/endoperoxide receptor activation is the predominant mechanism underlying the coronary occlusion which occurs in this model. Histologic evidence of platelet thrombi in the coronary arteries ofpatients who suffered sudden death (40) , the efficacy of aspirin in unstable angina (41) , and our recent demonstration that thromboxane A2 biosynthesis increases coincident with chest pain in patients with unstable angina (42) also implicate thromboxane-dependent platelet activation in human syndromes ofcoronary vascular occlusion. We conclude that thromboxane A2/prostaglandin endoperoxide receptor antagonists promise to be selective probes in further clarifying the role of thromboxane A2 formation in vivo and represent a novel approach to the treatment of vasoocclusive disease in man.
